<div id="readability-page-1"><p>Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Ionis Pharmaceuticals today and set a price target of $100.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Foroohar is a 3-star analyst with an average return of <span>3.0%</span> and a 46.39% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Ionis Pharmaceuticals.</p> <p>In addition to Leerink Partners, Ionis Pharmaceuticals also received a Buy from Wells Fargo’s Jim Birchenough in a report issued on December 8. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).</p></div>

IONS

<p>Leerink Partners analyst Mani Foroohar reiterated a Buy rating for Ionis Pharmaceuticals, setting a price target of $100. Foroohar, a 3-star analyst, has a 3.0% average return and a 46.39% success rate. Ionis also received a Buy rating from Wells Fargo's Jim Birchenough, while TR | OpenAI – 4o maintained a Hold rating.</p>

Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)